Semaglutide Research for Kidney Disease
An evidence-based overview of research examining Semaglutide in the context of kidney disease. This page synthesizes findings from peer-reviewed literature.
Research Summary
In FLOW (N=3,533), semaglutide lowered the prespecified major kidney disease-event composite by 24% relative to placebo in patients with type 2 diabetes and chronic kidney disease (HR 0.76). The trial was stopped early for efficacy. Semaglutide reduced the composite endpoint of kidney failure, sustained 50% eGFR decline, or death from kidney-related or cardiovascular causes. Subgroup estimates should not be read as proof of an identical effect at every level of baseline kidney function. The mechanism of kidney protection may involve improved glycemic control, blood pressure reduction, weight loss, and reduced inflammation. Semaglutide is now considered for kidney protection in addition to its metabolic and cardiovascular benefits.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.